We have also successfully demonstrated the potential of the combination therapy of platinum agents and CHD4 inhibitor by introducing the first-in-class SMARCA5/CHD4 inhibitor ED2-AD101 in ovarian cancer cells. This evidence concerns the gene CHD4 and ovarian carcinoma.